Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9UK55
UPID:
ZPI_HUMAN
Alternative names:
Serpin A10
Alternative UPACC:
Q9UK55; A5Z2A5; Q6UWX9; Q86U20
Background:
Protein Z-dependent protease inhibitor, also known as Serpin A10, plays a crucial role in blood coagulation. It inhibits the activity of coagulation protease factor Xa in the presence of PROZ, calcium, and phospholipids, and also inhibits factor XIa in the absence of cofactors. This regulatory mechanism is vital for maintaining hemostatic balance.
Therapeutic significance:
Understanding the role of Protein Z-dependent protease inhibitor could open doors to potential therapeutic strategies. Its pivotal function in coagulation and hemostasis suggests that targeting this protein could lead to novel treatments for clotting disorders.